logo
Plus   Neg
Share
Email

Coca-Cola Maintains FY20 Outlook; Provides COVID-19 Impact On Q1 - Quick Facts

Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference.

For fiscal 2020, the company continues to project comparable earnings to be about $2.25 per share on organic revenue growth of about 5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.26 per share on revenue growth of 4.7 percent to $39.05 billion for the year. Analysts' estimates typically exclude special items.

Meanwhile, the company said it currently estimates an approximate 2- to 3-point impact to unit case volume, 1- to 2-point impact to organic revenue and 1- to 2-penny impact to earnings per share for the first quarter due to COVID-19.

However, the situation with COVID-19 or coronavirus continues to evolve, and the company expects to provide more information during its next earnings call in April.

China ranks as the third-largest market in the world for The Coca-Cola Company in terms of unit case volume.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
Follow RTT
>